Neuraxis Q1 Revenue Climbs While Reimbursement Hurdles Delay Cash Conversion
NRXS•Neuraxis delivered robust first-quarter revenue growth while encountering delays in insurance coverage approvals for its neurosurgical monitoring services. Management warned these reimbursement issues are extending days-sales-outstanding and could pressure operating cash flows in the coming quarters.
1. Q1 Revenue Performance
Neuraxis reported year-over-year revenue growth in the first quarter, fueled by higher volumes of neurosurgical monitoring procedures and increased per-case reimbursement rates. The company noted that expanded service coverage in key regional markets contributed to this uptick.
2. Insurance Reimbursement Challenges
Management highlighted delays in securing coverage approvals from several major private insurers, resulting in a notable increase in days-sales-outstanding. These coverage issues have postponed billing recognition and created headwinds in working capital management.
3. Impact on Cash Flow and Outlook
The extended receivables cycle is expected to pressure cash flow conversion and could weigh on operating margins if reimbursement hurdles persist. Leadership stated that negotiating more favorable coverage terms remains a top priority to restore normal billing cycles.
